Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases.[@b1-copd-10-1371] According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report of 2014, COPD is a common preventable and treatable disease in which exacerbations and comorbidities contribute to the overall severity in individual patients.[@b1-copd-10-1371] COPD has been identified as the third leading cause of death globally,[@b2-copd-10-1371] and in 2010, 4.8% of the population was diagnosed with COPD worldwide.[@b3-copd-10-1371] Though alarming, these figures only partly represent the burden of the disease because a significant proportion of patients remain undiagnosed or misdiagnosed.[@b4-copd-10-1371]--[@b6-copd-10-1371] In the US and Europe, the rate of underdiagnosis was estimated to range from 12% to 86%.[@b7-copd-10-1371]--[@b9-copd-10-1371] The underutilization of spirometry as a diagnostic tool, the lack of awareness of physicians and patients about the clinical features of COPD (which includes breathlessness, chronic cough, and sputum production),[@b10-copd-10-1371] and the difficulty in differential diagnosis between COPD and asthma contribute significantly to this wide range of undiagnosed and misdiagnosed COPD patients.[@b11-copd-10-1371]--[@b13-copd-10-1371] Additionally, comorbidities that are commonly present along with COPD further hinder the detection of the disease,[@b9-copd-10-1371] and although COPD is a primary cause of death in some cases, it is often likely to be considered a contributing factor.[@b14-copd-10-1371] There is increasing evidence that early diagnosis and early treatment of COPD lead to improvements in lung function and quality of life, as well as a reduced risk of exacerbations.[@b15-copd-10-1371]

In Europe, prevalence rates of COPD were estimated to range between 2.1% and 26.1% depending on the country, age group, and methods used.[@b16-copd-10-1371] In Greece, COPD prevalence was estimated to range between 3% and 18.4%.[@b17-copd-10-1371]--[@b21-copd-10-1371] The variations observed in the prevalence rates are mainly due to the differences in the diagnostic methods (symptoms, physician reports, and spirometry), definition of COPD, age and sex distribution, and other population characteristics evaluated in each study.

This study -- the first in Greece to our knowledge -- aimed to 1) estimate the nationwide rates of newly diagnosed COPD cases and 2) assess a plethora of characteristics of COPD patients, including smoking habits, disease severity, compliance to treatment, and comorbidity, to raise treating physicians' awareness on the diagnosis and effective management of COPD in Greece.

Methods
=======

Study design
------------

The Greek Obstructive Lung Disease Epidemiology and health ecoNomics (GOLDEN) study was a noninterventional, nationwide epidemiological cross-sectional study conducted in Greece over a 6-month period.

To estimate the nationwide rate of newly diagnosed cases of COPD, both hospital-based and private respiratory medicine physicians were included in the study. Sampling was performed in three steps (details described by Papaioannou et al[@b22-copd-10-1371]--[@b26-copd-10-1371]): 1) the expected incident and prevalent COPD cases were estimated in each prefecture of Greece (52 administrative areas covering the whole country) and in total; 2) the expected incident COPD cases were estimated per pulmonologist in each prefecture; and lastly 3) on the basis of the ratios of expected COPD cases per pulmonologist per prefecture, three levels of sampling zones were created ([Figure 1](#f1-copd-10-1371){ref-type="fig"}). Zone A: areas with very large hospitals, very high density of respiratory medicine physicians, and low ratios of expected COPD cases per physician; Zone B: areas with large respiratory medicine departments and many private practitioners; and Zone C: all other areas with mostly aging rural populations and few respiratory medicine physicians.

Pulmonologists from 45 respiratory medicine departments throughout Greece participated in the study. In total, 199 pulmonologists (124 private practitioners and 75 hospital doctors) provided data for this study. The total number of pulmonologists in Greece is approximately 1,800. According to this number, the sample of pulmonologists that participated in the study represents \~11% of the total pool of the specialty. Data collection was performed over a period of 6 months (October 2010--March 2011). During the 6 months of the study period, each pulmonologist was asked 1) to invite the first 30 consecutive COPD patients visiting their clinic/office and who satisfied the inclusion and exclusion criteria to register for the study and 2) to monitor all newly diagnosed cases (cases diagnosed for the first time as having COPD during the specific study period) for a period of 24 weeks.

Patients
--------

Patients could be recruited in the GOLDEN study if they provided their written informed consent and fulfilled the following inclusion and exclusion criteria:

Inclusion criteria were as follows: patients \>40 years of age, with a diagnosis of COPD, based on GOLD 2011 criteria,[@b11-copd-10-1371] and with the ability to provide data on their medical history. Exclusion criteria consisted of patients who had participated in a similar study a month prior to their enrollment or had asthma.

Ex-smokers were defined as smokers who had quit smoking for at least 12 months. Smoking history was measured by pack-years, defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years of smoking. According to their smoking history, subjects were classified into three categories: never-smokers, ex-smokers, and current smokers. Compliance to therapy was assessed from physicians according to the monthly prescription of medication and the patients' and/or relatives' reporting on the regular use of the prescribed medication.

Pre- and postbronchodilation spirometry measurements were performed in all study subjects according to the routine monitoring of COPD patients in daily clinical practice. Forced expiratory volume in 1 second (FEV~1~), forced vital capacity (FVC), and the FEV~1~/FVC ratio were recorded. Post-bronchodilator values (30 minutes after the administration of 400 μg salbutamol with a spacer) were used for the evaluation of airflow severity, according to GOLD 2011 guidelines (Stage 1: mild COPD, FEV~1~ ≥80.0% predicted; Stage 2: moderate COPD, 50.0%≤ FEV~1~ \<80.0% predicted; Stage 3: severe COPD, 30.0%≤ FEV~1~ \<50.0%; Stage 4: very severe COPD, either FEV~1~ \<30.0% or FEV~1~ \<50.0% predicted with chronic respiratory failure).[@b11-copd-10-1371]

A second data set included patients with "newly diagnosed" COPD who were first diagnosed during the study period (patients who were referred for the first time to a pulmonologist with diagnosis established through spirometry). The number of newly diagnosed patients was recorded through the retrospective completion of questionnaires that corresponded to a once-per-week evaluation of the new patients for the total study duration of 6 months. In calendar months, the data collection phase lasted from September to March. The characteristics of the newly diagnosed patients recorded in this study included sex, age, disease type (bronchitis/emphysema) and airflow limitation (according to GOLD 2011 classification), place of residence, and smoking history.

The protocol was approved by the ethics committees of the participating research centers and the National Organization for Medicines. The study was designed, implemented, and reported in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/83/EC and US Code of Federal Regulations Part 21), and in accordance with the ethical principles according to the Declaration of Helsinki.

Statistical methods and analysis
--------------------------------

Categorical variables were presented using frequency and rate, whereas continuous variables were presented using descriptive statistics (median and interquartile range \[IQR\]).

The rate ratios of the newly diagnosed patients were estimated using the mixed-effect Poisson model. Dependence of the rate of newly diagnosed cases with COPD on the prefectures, geographic divisions, hospitals, employment of the pulmonologist (hospital- or private-based practice), and season was also determined.

The analysis of COPD diagnosis rate was based on the hypothesis that the number of new COPD cases follows a Poisson distribution. In order to model the repeated observations per pulmonologist (assumed to affect variability), a mixed-effects Poisson model was applied. The random effect was assumed to follow the gamma distribution.

Results
=======

Demographic characteristics of prevalent COPD cases (1st data set)
------------------------------------------------------------------

Data from 6,125 patients were collected in the study. The baseline and clinical characteristics of the total sample are shown in [Table 1](#t1-copd-10-1371){ref-type="table"}. The median age of the study participants was 68 years (IQR: 60.0--75.0) and the male-to-female ratio was 2.5:1. The median duration of COPD was 10 years (IQR: 5.0--15.0). Never-smokers accounted for only 10.2% of the evaluated patients. A large proportion of the enrolled patients (18%) were newly diagnosed, many of whom had significant airflow limitation at the time of diagnosis. According to GOLD 2011 criteria, the majority of the patients were assessed with moderate or severe airflow limitation (35.4% and 25.6%, respectively).

Approximately 82% reported at least one concomitant disease, with the most common comorbid condition being hypertension (55.3%).

Almost half of the patients recruited (54%) reported going through preventative vaccination and only 2.7% of the patients were part of rehabilitation programs. The majority of the patients (61.3%) were under maintenance treatment, mostly with bronchodilators (64.4%). A total of 61.4% reported using inhaled corticosteroids (ICSs), while fixed-dose combinations of long-acting β~2~-agonists + ICSs were reported as maintenance treatment by 39.9% of the patients. Approximately 55% of the patients in the study reported never forgetting to take their medication. The majority (81%) of the patients reported a preference for fewer inhalations of their bronchodilator therapy.

Differences in the characteristics of newly diagnosed and previously diagnosed COPD cases are also illustrated in [Table 1](#t1-copd-10-1371){ref-type="table"}. Compared to cases with an earlier diagnosis of COPD, cases diagnosed within the past year included more females, less ex-smokers, were largely classified under stages 1 and 2, less frequent diagnosis of emphysema or mixed disease, and a low number of comorbidities ([Table 1](#t1-copd-10-1371){ref-type="table"}). Overall, the compliance to therapy was better among newly diagnosed cases, but a high percentage of patients forgot to take their medication regularly compared to the previously diagnosed patients (5.9% vs 4.5%; [Table 1](#t1-copd-10-1371){ref-type="table"}).

Airflow limitation severity, defined by GOLD 2011 criteria, was significantly related to older age, male sex, obesity, ex-smoker status, and presence of more concomitant diseases (*P*\<0.001) ([Figure 2](#f2-copd-10-1371){ref-type="fig"} and [Table 2](#t2-copd-10-1371){ref-type="table"}).

COPD cases diagnosed during the follow up period (2nd data set)
---------------------------------------------------------------

### Rate of new COPD cases

A total of 5,030 new cases of COPD were recorded by the 199 pulmonologists in a median follow-up time of 5.60 months (IQR: 5.37--5.83). The representativeness of the sample of pulmonologists per prefecture is illustrated in [Table 3](#t3-copd-10-1371){ref-type="table"}, while the rate of new diagnoses per prefecture is illustrated in [Figure 3](#f3-copd-10-1371){ref-type="fig"}. The rate of newly diagnosed cases with COPD based on the mixed-effect Poisson model was 18.2 (95% confidence interval \[CI\]: 14.9--22.3) per pulmonologist/3 months. Characteristics of the newly diagnosed patients with COPD are presented in [Table 4](#t4-copd-10-1371){ref-type="table"}.

Geographical distribution of new COPD cases
-------------------------------------------

There was a statistically significant heterogeneity among pulmonologists adjusted for geographic division; rates were found to be higher in populated geographic regions of Greece. The majority of the newly diagnosed COPD patients resided in Athens (32.5%) and other urban cities (32.3%; urban cities defined as cities with \>10,000 population).

Statistically significant differences were observed in the rate of newly diagnosed cases depending on the hospital (*P*=0.009), setting of the pulmonologist (hospital- or private-based practice; *P*\<0.001), season (*P*\<0.001), and the level of the sampling zone (*P*=0.022) (data provided in [Tables S1](#SD1-copd-10-1371){ref-type="supplementary-material"}--[S4](#SD4-copd-10-1371){ref-type="supplementary-material"}, respectively). A statistically significant heterogeneity existed among pulmonologists when these factors were taken into consideration (*P*\<0.001 for each factor).

The multivariate analysis of the rate of new COPD diagnoses is presented in [Table 5](#t5-copd-10-1371){ref-type="table"}. A statistically significant difference in the incidence of newly diagnosed cases was observed among prefectures (*P*\<0.001) taking into account the setting (hospital- or private-based pulmonologist) and the seasonal influence ([Table 5](#t5-copd-10-1371){ref-type="table"}). Hospital-based pulmonologists reported a lower rate of newly diagnosed COPD cases compared to private-based pulmonologists (lower by 70.4%) when the prefecture and the season were also considered (*P*\<0.001; [Table 5](#t5-copd-10-1371){ref-type="table"}).

The rate of new COPD diagnoses was also affected by the season, with lower reporting noted during the warmer months (lower by 18.5%) compared to colder months, when the prefecture and the setting were taken into consideration (*P*\<0.001; [Table 5](#t5-copd-10-1371){ref-type="table"}). When all parameters of the multivariate model were considered, a statistically significant heterogeneity was observed among pulmonologists (*P*\<0.001; 95% CI random effect: 1.15 \[0.92--1.43\]).

On the basis of the assumption that pulmonologists see the more severe cases, an additional analysis was carried out considering only GOLD 2--4 stages of COPD. The calculated rate of these cases was 10.7 (95% CI: 8.7--13.2) per pulmonologist/3 months.

Similar to the results observed for overall cases, statistically significant differences were observed in the incidence rate of newly diagnosed cases considering only GOLD 2--4 stages depending on the geographic divisions, setting of the pulmonologist, and season (*P*\<0.001 for all factors).

Discussion
==========

The GOLDEN study has recorded data that allow for the description of various characteristics of COPD patients in Greece.

According to the current study findings, COPD was more prevalent among older adults, men, and smokers, which is consistent with findings of previous studies in the Greek population.[@b18-copd-10-1371]--[@b20-copd-10-1371] The current study is the first nationwide study reporting new findings since 2004 and consists of a significant sample size. Direct comparison of our results with past studies is also difficult to establish, owing to the fact that different age distributions, regions, populations, and time periods of assessment were evaluated in each study.

The findings of the current study are also in accordance with those of the studies conducted worldwide, with high COPD prevalence observed among elderly individuals, men, and smokers.[@b27-copd-10-1371]--[@b31-copd-10-1371] However, differences were also noted. The current study in Greece observed more cases of COPD in overweight individuals, whereas studies conducted in the US and Norway reported high prevalence among underweight or severely obese individuals.[@b27-copd-10-1371],[@b29-copd-10-1371] In contrast to our findings, higher prevalence rates of COPD were observed among women than men in the US,[@b30-copd-10-1371] while in Africa, no significant effect of sex was seen on the prevalence of COPD.[@b31-copd-10-1371]

Interestingly, patients diagnosed within the past year were less frequently diagnosed with emphysema or mixed disease, as well as having a high number of comorbid conditions, although less in number compared to patients diagnosed earlier. These study findings support the significance of early diagnosis and intervention among heavy smokers and males, as early diagnostic and educational strategies could enhance disease management and compliance to treatment.[@b32-copd-10-1371]

Interestingly, half of the patients in the GOLDEN study were assessed as having mild or moderate airflow limitation (Stages 1 and 2), and according to the new GOLD guidelines, they would be expected to fall in groups A and B if they had either \<2 exacerbations in the previous year or no hospitalizations. However, a significant percentage of these patients reported being under treatment with ICSs (which is recommended in patients with severe or very severe airflow limitation and/or hospitalizations or ≥2 exacerbations per year; groups C and D), indicating a low rate of adherence to global recommendations by the treating physicians.[@b1-copd-10-1371] In addition, the low rates of preventive vaccination and rehabilitation highlight the significance of increasing awareness of these interventions for the effective management of COPD, as recommended by GOLD.[@b1-copd-10-1371]

High rates of nonadherence to COPD treatment were also recorded in our study. The high proportion of patients forgetting to take their medication might be due to the presence of multiple comorbidities and thus they may need to take multiple treatments, related to higher age, while complex dosing schedules and perception of limited efficacy can also cause low compliance rates.[@b33-copd-10-1371] Extra care should therefore be taken in educating COPD patients on the significance of compliance to therapy to reduce symptoms and future risk. In agreement with previously reported data,[@b17-copd-10-1371],[@b34-copd-10-1371]--[@b36-copd-10-1371] the most commonly reported comorbidities in the studied population were hypertension, diabetes mellitus, heart failure, and gastroesophageal reflux. Sensitization of primary care physicians treating these conditions among the common COPD symptoms might provide a means to refer them for lung function testing and earlier COPD diagnosis.[@b37-copd-10-1371]

The rate of newly diagnosed COPD cases observed was much higher than expected based on the international literature and \>5 times higher than that calculated during the design of the study. Recent data from a Dutch study reported 1,713 newly diagnosed cases of COPD in a mean follow-up time of 3.4 years (standard deviation = ±3.2 years).[@b38-copd-10-1371] A longitudinal cohort study conducted in Ontario, Canada, estimated the annual incidence rates of COPD from 1996 to 2007 to be 61,998 to 55,903.[@b39-copd-10-1371] A prospective cohort study identified 648 cases of incident COPD after a median follow-up time of 11 years in the Netherlands.[@b40-copd-10-1371] Compared to the incidence rates reported in the above-mentioned studies, the GOLDEN study recorded a total of 5,030 new cases of COPD in a mean follow-up time of 5.60 months. These differences in incidence rates can perhaps be attributed to differences in the definitions of COPD, health care settings, geographical divisions, characteristics of the study populations (with respect to age, sex, and smoking status), and methodology used for assessing COPD. An interesting finding is that the highest rates of newly diagnosed cases were recorded in urban areas and mostly by private pulmonologists. This might be indicative of the reduced rates of COPD diagnosis in rural areas, especially due to the lack of specialized pulmonologists to perform spirometry.

Because the majority of the newly diagnosed patients had mild or moderate airflow limitation (78.2%), it is necessary to implement routine spirometric evaluations to identify the disease in its earlier stages. Detection of these patients at early stages of airflow limitation might assist in the optimization of disease management in the long term. As smoking is one of the main contributing causes of COPD,[@b41-copd-10-1371] spirometry could be used in current and ex-smokers with or without respiratory symptoms as a diagnostic tool to evaluate the possible presence of COPD. These measures may identify patients with undiagnosed COPD, and early diagnosis can lead to adequate management of such cases.

As with all observational studies, the GOLDEN study has strengths and weaknesses. The foremost strength is that this is the first study to assess newly diagnosed cases of COPD throughout Greece in a large sample size, allowing the collation of detailed information on various patient aspects. Furthermore, the use of spirometry in our study provides an additional validation of the classification of disease severity. The limitation of our study is the possibility that our results might have suffered an overestimation bias (overreporting bias) most probably due to the retrospective recording of newly diagnosed COPD cases and the high per capita consumption of cigarettes among the Greek population.

Conclusion
==========

The GOLDEN study reflects the real-life profile of COPD patients in Greece. The study has observed predominance of the elderly, men, smokers, overweight and obese individuals, moderate airflow limitation, and high comorbidity among COPD patients. In addition, results revealed a high proportion of newly diagnosed cases of COPD, relatively low compliance to treatment guidelines, high rates of nonadherence to COPD treatment, and an increased preference for simpler treatment options (fewer inhalations). Substantial rates of new COPD diagnoses in Greece were also documented, indicating the need to increase awareness around the disease and its effective management. These data provide a framework that could be used by health professionals to adequately diagnose and manage COPD. However, more studies in well-defined samples with similar patient populations, using standard diagnostic tools are required to effectively integrate strategies to prevent and manage COPD in Greece.

Supplementary materials
=======================

###### 

Dependence of the rate of newly diagnosed cases with COPD per hospital

                                           RR      95% CI            *P*-value
  ---------------------------------------- ------- ----------------- -----------
  **Hospital**                                                       0.009
  GH Ag. Dimitrios                         1                         
  GH Amalia Fleming                        0.96    (0.179, 5.159)    0.962
  GH Venizelio of Heraklion                0.25    (0.036, 1.751)    0.163
  GH of Corfu                              7.333   (1.487, 36.169)   0.014
  GH of Kavala                             0.403   (0.090, 1.811)    0.236
  GH of Kalamata                           2.4     (0.473, 12.170)   0.291
  GH of Karditsa                           0.16    (0.020, 1.312)    0.088
  GH of Kozani Mamatseio                   0.8     (0.146, 4.382)    0.797
  GH of Komotini                           0.824   (0.155, 4.366)    0.820
  Sismanogleio                                                       
  GH of Lamia                              1.8     (0.325, 9.982)    0.501
  GH Papanikolaou                          0.188   (0.034, 1.041)    0.056
  GH of Pyrgos A                           0.636   (0.111, 3.656)    0.612
  Papandreou                                                         
  GH of Rethymnon                          1.208   (0.238, 6.136)    0.819
  GH of Serres                             1       (0.186, 5.374)    1.000
  GH Sismanogleio                          0.762   (0.190, 3.046)    0.700
  GH of thorax diseases                    0.774   (0.217, 2.757)    0.693
  Sotiria                                                            
  GH of Chios Skylitseio                   1.04    (0.195, 5.548)    0.963
  GH of Chalkida                           2.32    (0.457, 11.780)   0.310
  GH of Chania Ag. Georgios                0.923   (0.172, 4.961)    0.926
  GUH Evaggelismos                         0.448   (0.099, 2.031)    0.298
  GUH of Larisa                            1.571   (0.306, 8.083)    0.589
  GUH of Nikaia                            1.36    (0.260, 7.105)    0.715
  GUH Papageorgiou                         0.455   (0.074, 2.777)    0.393
  Special Hospital of Thorax               0.768   (0.178, 3.325)    0.725
  Diseases of West Greece                                            
  UGH Attikon                              0.56    (0.097, 3.217)    0.516
  UGH of Heraklion Pepagni                 0.88    (0.162, 4.770)    0.882
  University Hospital of Alexandroupolis   1.875   (0.370, 9.508)    0.448

**Note:** Results from mixed-effect Poisson model.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; GH, General Hospital; RR, rate ratios; UGH, University General Hospital; GUH, General University Hospital.

###### 

Dependence of the rate of newly diagnosed cases with COPD on the setting of the pulmonologist (hospital or private based)

                 RR      95% CI           *P*-value
  -------------- ------- ---------------- -----------
  **Hospital**                            
  No             1                        
  Yes            0.297   (0.193, 0.458)   \<0.001

**Note:** Results from mixed-effect Poisson model.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratios.

###### 

Dependence of the rate of newly diagnosed cases with COPD on season

                                  RR      95% CI           *P*-value
  ------------------------------- ------- ---------------- -----------
  **Months (April--September)**                            
  No                              1                        
  Yes                             0.817   (0.771, 0.865)   \<0.001

**Note:** Results from mixed-effect Poisson model.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratios.

###### 

Dependence of the rate of newly diagnosed cases with COPD on the sample level

                     RR      95% CI           *P*-value
  ------------------ ------- ---------------- -----------
  **Sample level**                            0.022
  A                  1                        
  B                  0.775   (0.445, 1.350)   0.368
  C                  1.681   (1.069, 2.645)   0.025

**Note:** Results from mixed-effect Poisson model.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratios.
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**Notes:** Zone A, areas with very large hospitals, very high density of respiratory medicine physicians, and low ratios of expected COPD cases per physician; Zone B, areas with large respiratory medicine departments and many private practitioners; Zone C, all other areas with mostly aging rural populations and few respiratory medicine physicians.](copd-10-1371Fig1){#f1-copd-10-1371}

![Descriptive statistics of the study participants according to airflow limitation as defined by GOLD guidelines.\
**Abbreviations:** BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease.](copd-10-1371Fig2){#f2-copd-10-1371}

![Dependence of the rate of newly diagnosed cases with COPD on prefectures (results from mixed-effect Poisson model).\
**Notes:** All the prefectures studied were compared against Attica, wherein higher number of cases was reported. Highlighted data represent significant results. Log RR \>0 indicates higher incidence, while value \<0 indicates lower incidence.\
**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratios.](copd-10-1371Fig3){#f3-copd-10-1371}

###### 

Demographic and clinical characteristics of the prevalent cases

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic characteristics                                                      Total (N=6,125)[a](#tfn1-copd-10-1371){ref-type="table-fn"}   "Old" cases[\*](#tfn3-copd-10-1371){ref-type="table-fn"}\   Cases (%) first diagnosed within the past year[b](#tfn2-copd-10-1371){ref-type="table-fn"}\
                                                                                                                                                 (N=4,850)                                                   (N=1,064)
  -------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Male/female                                                                      4,367/1,758 (71.3/28.7)                                       3,490/1,360 (72/28)                                         720/344 (67.7/32.3)

  Duration of COPD (years)                                                         10.0 (5.0, 15.0)                                              10.0 (5.0, 15.0)                                            --

  Body mass index[b](#tfn2-copd-10-1371){ref-type="table-fn"}                                                                                                                                                

   Normal (18.5--25 kg/m^2^)                                                       1,574 (25.9)                                                  1,245 (25.9)                                                277 (26.2)

   Overweight (25--30 kg/m^2^)                                                     2,715 (44.7)                                                  2,133 (44.3)                                                495 (46.8)

   Obese (\>30 kg/m^2^)                                                            1,781 (29.3)                                                  1,436 (29.8)                                                286 (27.0)

  Smoking status (N=5,999)                                                                                                                                                                                   

   Current smokers                                                                 2,869 (47.8)                                                  2,126 (44.6)                                                676 (64.8)

   Ex-smokers                                                                      2,519 (42)                                                    2,155 (45.2)                                                271 (26.0)

   Never-smokers                                                                   611 (10.2)                                                    488 (10.2)                                                  96 (9.2)

  Diagnosis (N=5,914)                                                                                                                                                                                        

   Chronic bronchitis                                                              2,856 (48.3)                                                  2,260 (46.6)                                                596 (56.0)

   Emphysema                                                                       801 (13.5)                                                    659 (13.6)                                                  142 (13.3)

   Mixed disease                                                                   2,092 (35.4)                                                  1,808 (37.3)                                                284 (26.7)

   Undefined respiratory disease                                                   165 (2.8)                                                     123 (2.5)                                                   42 (3.9)

  GOLD 2011 classification of severity of airflow limitation (N=6,114)                                                                                                                                       

   1                                                                               1,181 (19.3)                                                  755 (15.6)                                                  398 (37.4)

   2                                                                               2,167 (35.4)                                                  1,705 (35.2)                                                399 (37.5)

   3                                                                               1,567 (25.6)                                                  1,302 (26.8)                                                198 (18.6)

   4                                                                               1,199 (19.6)                                                  1,088 (22.4)                                                69 (6.5)

  Number of exacerbations in the past year                                         2.0 (0.0, 3.0)                                                --                                                          --

  Would prefer the inhaled bronchodilator therapy to include fewer inhalations     4,832 (81.1)                                                  3,978 (83.2)                                                691 (70.3)

  Compliance to therapy                                                                                                                                                                                      

   Never/almost never                                                              3,242 (54.5)                                                  2,527 (52.4)                                                604 (65.1)

   \<3 times a month                                                               1,276 (21.5)                                                  1,088 (22.6)                                                143 (15.4)

   1 time a week                                                                   666 (11.2)                                                    570 (11.8)                                                  70 (7.5)

   \>1 time a week                                                                 483 (8.1)                                                     415 (8.6)                                                   56 (6.0)

   Almost every day                                                                277 (4.7)                                                     218 (4.5)                                                   55 (5.9)

  Respiratory failure-type I                                                       1,422 (23.4)                                                  1,213 (25.2)                                                142 (13.4)

  Respiratory failure-type II                                                      624 (10.3)                                                    557 (11.6)                                                  43 (4.1)

  Use of nebulizer                                                                 1,316 (21.6)                                                  1,188 (24.5)                                                73 (6.9)

  Noninvasive mechanical ventilation[b](#tfn2-copd-10-1371){ref-type="table-fn"}   201 (3.3)                                                     156 (3.2)                                                   27 (2.5)

  Therapy with oxygen                                                              1,048 (17.1)                                                  976 (20.1)                                                  52 (4.9)

  Concomitant diseases                                                                                                                                                                                       

   0                                                                               1,093 (18.2)                                                  792 (16.6)                                                  269 (25.7)

   1                                                                               1,567 (26.1)                                                  1,186 (24.8)                                                336 (32.1)

   2                                                                               1,430 (23.8)                                                  1,130 (23.7)                                                239 (22.8)

   3                                                                               982 (16.4)                                                    829 (17.4)                                                  128 (12.2)

   4+                                                                              934 (15.6)                                                    841 (17.6)                                                  76 (7.3)

  Common comorbid conditions                                                                                                                                                                                 

   Hypertension                                                                    3,379 (55.3)                                                  2,797 (57.7)                                                470 (44.2)

   Diabetes mellitus                                                               1,253 (20.6)                                                  1,034 (21.4)                                                177 (16.7)

   Heart failure                                                                   1,185 (19.4)                                                  1,021 (21.1)                                                119 (11.2)

   Gastroesophageal reflux                                                         934 (15.3)                                                    767 (15.8)                                                  144 (13.6)[b](#tfn2-copd-10-1371){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Data are presented as median (interquartile ranges) for numerical variables or as number (%) for categorical variables.

Differences were not statistically significant; all others were significant (*P*\<0.001).

"Old" refers to cases diagnosed for at least two years.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Descriptive statistics of study participants according to severity of COPD (GOLD 2011)

  Characteristics                            Severity of COPD                                                                
  ------------------------------------------ ------------------- ------------------- ------------------- ------------------- ---------
  Age (years)                                63.0 (53.0, 71.0)   67.0 (59.0, 74.0)   67.0 (60.0, 75.0)   72.0 (66.0, 78.0)   \<0.001
  Duration of COPD (years)                   5.0 (2.0, 10.0)     8.0 (4.0, 11.0)     10.0 (5.0, 15.0)    10.0 (6.0, 19.0)    \<0.001
  Pack-years                                 35.5 (20.0, 52.5)   40.0 (25.0, 61.3)   45.0 (20.0, 64.0)   60.0 (37.5, 83.6)   \<0.001
  FEV~1~ before bronchodilation (%)          80.0 (70.0, 87.0)   65.0 (58.0, 71.0)   52.0 (43.0, 67.0)   43.0 (29.0, 54.5)   \<0.001
  FEV~1~ after bronchodilation (%)           82.0 (75.0, 90.0)   68.0 (61.0, 75.0)   58.0 (47.0, 74.0)   46.0 (32.0, 59.0)   \<0.001
  Number of exacerbations in the past year   1.0 (0.0, 2.0)      1.0 (0.0, 2.0)      2.0 (1.0, 3.0)      2.0 (1.0, 4.0)      \<0.001

**Notes:** Data are presented as median (interquartile ranges) for numerical variables.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Representativeness of COPD diagnoses per prefecture

                   Newly diagnosed   Population as % of total   *P*-value   
  ---------------- ----------------- -------------------------- ----------- -------
  **Prefecture**                                                            0.008
  Thrace           219 (4.6)         35 (3.3)                   5.6         
  Macedonia        1,052 (22.1)      214 (20.4)                 19.8        
  Epirus           86 (1.8)          11 (1.0)                   3.1         
  Thessaly         286 (6.0)         46 (4.4)                   6.7         
  Central Greece   1,861 (39.0)      461 (43.9)                 46.7        
  Peloponnese      607 (12.7)        131 (12.5)                 5.4         
  Aegean Islands   180 (3.8)         31 (3.0)                   5.0         
  Ionian Islands   82 (1.7)          25 (2.4)                   1.9         
  Crete            396 (8.3)         95 (9.1)                   5.7         

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Characteristics of newly diagnosed patients with COPD in Greece

  Characteristics                                                  Male, %   Female, %   Total, %
  ---------------------------------------------------------------- --------- ----------- ----------
  **Disease**                                                                            
  Chronic bronchitis                                               50.09     57.71       52.07
  Emphysema                                                        16.55     11.94       15.35
  Chronic bronchitis and emphysema                                 33.36     30.35       32.58
  **GOLD 2011 classification of severity of airflow limitation**                         
  0--1                                                             29.53     43.63       33.21
  2                                                                46.40     41.15       45.03
  3                                                                19.34     13.52       17.82
  4                                                                4.74      1.71        3.95
  **Smoking status**                                                                     
  Smokers                                                          77.41     75.11       76.74
  Ex-smokers                                                       19.88     19.33       19.72
  Never-smokers                                                    2.71      5.56        3.54
  **Age (years)**                                                                        
  ≤44                                                              1.54      1.53        1.54
  45--49                                                           4.63      7.68        5.52
  50--54                                                           10.09     13.01       10.95
  55--59                                                           18.45     23.28       19.86
  60--64                                                           22.41     25.51       23.31
  65--69                                                           21.10     17.28       19.98
  70--74                                                           12.73     7.41        11.18
  75--79                                                           6.09      2.90        5.16
  ≥80                                                              2.95      1.41        2.50

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Multivariate analysis of the rate of new diagnoses of COPD

                                         RR      95% CI            *P*-value
  -------------------------------------- ------- ----------------- -----------
  **Prefecture**                                                   \<0.001
  Central Greece                         1                         
  Thrace                                 0.973   (0.390, 2.427)    0.954
  Peloponnese                            1.167   (0.687, 1.984)    0.567
  Crete                                  0.286   (0.154, 0.534)    \<0.001
  Macedonia                              0.578   (0.362, 0.924)    0.022
  Thessaly                               0.307   (0.139, 0.678)    0.003
  Aegean Islands                         0.576   (0.212, 1.568)    0.281
  Ionian Islands                         5.526   (0.642, 47.569)   0.120
  Epirus                                 0.68    (0.146, 3.174)    0.624
  **Hospital**                                                     
  No                                     1                         
  Yes                                    0.296   (0.194, 0.450)    \<0.001
  **Warmer months (April--September)**                             
  No                                     1                         
  Yes                                    0.815   (0.769, 0.864)    \<0.001

**Notes:** Results from the mixed-effects Poisson model.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; RR, rate ratios.
